English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, July 26, 2018
エーザイとバイオジェン、BAN2401の早期アルツハイマー病を対象とした臨床第II相試験結果の詳細をアルツハイマー病協会国際会議(AAIC2018)にて発表
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018
Thursday, July 19, 2018
Latest Data on Eisai's Alzheimer's Disease / Dementia Pipeline to be Presented at Alzheimer's Association International Conference (AAIC) 2018
エーザイ、アルツハイマー病協会国際会議2018(AAIC2018)においてアルツハイマー病/認知症領域の開発品に関する最新データを発表
Wednesday, July 18, 2018
エーザイ、肥満症治療剤「BELVIQ(R)」が大規模な心血管疾患アウトカム試験にて良好なトップライン結果を取得
Eisai: Positive Topline Results Obtained from Large-Scale Cardiovascular Outcomes Trial of Anti-Obesity Agent BELVIQ
Wednesday, July 11, 2018
佐藤製薬とエーザイ、経口抗真菌剤「ネイリン(R)カプセル100mg」新発売のお知らせ
Eisai: Oral Antifungal Agent Nailin Capsules 100mg to be Launched in Japan
Tuesday, July 10, 2018
Eisai: Oral Presentation on Phase II Clinical Study Results of BAN2401 to be Presented at Alzheimer's Association International Conference (AAIC) 2018
エーザイ、アルツハイマー病協会国際会議2018(AAIC2018)においてBAN2401の臨床第II相試験結果を口頭発表

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575